Journal Article Summary
The article discusses the safety and efficacy of newer generation H1-antihistamines compared to first-generation H1-antihistamines for treating allergic rhinitis and urticaria. This topic is important because first-generation antihistamines, such as diphenhydramine, are widely used despite their significant side effects, including sedation and cognitive impairment. The Canadian Society of Allergy and Clinical Immunology (CSACI) emphasizes that newer antihistamines should be the preferred choice due to their improved safety profile and effectiveness.
The authors reviewed existing research and clinical trials to compare the two classes of antihistamines. They found that newer generation antihistamines are not only safer but also have a faster onset of action and better efficacy than their older counterparts. Despite the evidence supporting the use of newer antihistamines, first-generation options remain popular due to their over-the-counter availability and long-standing familiarity among patients and healthcare providers.
Limitations of the study include the ongoing overuse of first-generation antihistamines, which can lead to serious health risks, including accidents and fatalities. Patients should be aware of these risks and discuss with their healthcare professionals the best treatment options for allergic conditions. The article suggests that first-generation antihistamines should be reserved for rare cases and potentially regulated to be available only behind the counter to enhance patient safety.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Fein Michael N., Fischer David A., O’Keefe Andrew W., Sussman Gord L.. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology 2019. DOI: 10.1186/s13223-019-0375-9. PMID: 31582993. PMCID: PMC6771107.
Featured Pill Pals Product
Loratadine 10 mg --- 300 Count Bottle --- Generic For Claritin --- Major / Rugby --- Over The Counter
Loratadine 10 mg — 300 Count Bottle — Generic For Claritin — Major / Rugby — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
